Lonza Group will purchase Genentech’s manufacturing facility in Porrino, Spain, for $150 million. This facility has a biologic manufacturing capacity of 40,000 L and is currently dedicated to ...

A $1.2 billion deal by Swiss biotech firm Lonza to purchase the Vacaville Genentech site ... United Kingdom, Portsmouth, New Hampshire, Singapore and Porrino, Spain. Lonza also acquired ...

South San Francisco, CA and Basel, Switzerland (Nov. 8)-Genentech, Inc. (South San Francisco, CA, www.gene.com) and the contract manufacturer Lonza Group (Basel, Switzerland, www.lonza.com) entered ...

Lonza built the cell ... which Lonza paid $150 million to acquire Genentech’s mid-scale Avastin-producing mammalian biopharmaceutical plant in Porrino, Spain. Lonza is also building its ...

Switzerland's Lonza has struck a deal to buy a manufacturing plant in Spain from Genentech for $150 million. Genentech, meanwhile, gained an option to buy a huge new manufacturing plant Lonza is ...

Genentech Inc. agreed Wednesday to sell a factory that makes Avastin in Spain to Lonza Group Ltd. for $150 million. The 310-worker factory, at Porrino, is licensed by the U.S. Food and Drug ...

Lonza plans to invest approximately CHF 850 million (US$936 million) to build new state-of-the-art mammalian manufacturing facilities at its Visp, ... Spain. In Portsmouth, the company plans to build ...

Christian Morello, Vice President, Head of Bioconjugates, Lonza, commented: “The relationship with our valued partner has evolved over the years to incorporate all stages of bioconjugate manufacturing ...

Lonza expects the Portsmouth plant to come online in 2023. The company will hire 250 people to work there. "In recent months, the COVID-19 pandemic has placed the spotlight on supply chains and ...